H. Richard Casdorph, M.D., Ph.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
Longitudinal studies on the hypolipidemic effect of cholestyramine have been conducted on 103 hyperlipidemic patients (representing 1,728 patient-months of therapy). Cholestyramine was administered in doses of 12 to 24 g/day. Various lipid values have been studied. Serum cholesterol was measured by Auto-Analyzer. The average cholesterol for the 103 patients was reduced from 317 to 199.7 mg/100 ml, an average reduction of 117.3 mg/100 ml (-19.8%). Percent reduction by type was 54 type II patients, -19.8%; 1 type III patient, -21%; 33 type IV patients, -20.2%; and 15 untyped hypercholesteremic patients, -21.5%. No significant change in the serum triglycerides was observed.
Casdorph HR. The Efficacy and Safety of Cholestyramine Therapy in Hyperlipidemic Patients.. Ann Intern Med. ;74:818. doi: 10.7326/0003-4819-74-5-818_2
Download citation file:
Published: Ann Intern Med. 1971;74(5):818.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use